VALO TX is a developer of a novel cancer immunotherapy that is projected to transform the lives of millions of cancer patients. Our unique approach to immunotherapy in cancer, based on an oncolytic virus non-covalently combined with tumor-specific peptides, delivers a highly immunogenic and unique tumor vaccination platform.